News 2019

OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

First Orphan Drug Designation for OBI-999, a novel first-in-class Antibody-Drug Conjugate targeting Globo H, a glycolipid antigen found on multiple tumor types TAIPEI, Taiwan, Dec. 26, 2019 — OBI Pharma, Inc., a …

OBI Pharma Announces Initiation of a Phase 1/2 Study of Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999.

TAIPEI, Taiwan, December 18, 2019 ─ OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced the initiation of a Phase 1/2 clinical trial (ClinicalTrials.gov Identifier: NCT04084366) of OBI-999, an …

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999

First Clinical Trial to test the Safety and Efficacy of based on an ADC (Antibody Drug Conjugate) targeting Globo H, a glycolipid antigen found on multiple tumor types. TAIPEI, Taiwan, …

OBI Pharma Announces Poster Presentations at AACR 2019 for Novel Globo H Immuno-Oncology Therapeutics: OBI-888 and OBI-999

Poster Presentations to highlight on mechanism of action, anti-tumor efficacy and pharmacokinetics profile for OBI-888 (Globo H mAb) and OBI-999 (Globo H ADC) TAIPEI, Taiwan, March 28, 2019/OBI Pharma, Inc. …

New Scientific Research provides link between Globo-series glycosphingolipids (GSLs) antigens and tumor survival in Breast Cancer

Study supports the anti-Globo series Cancer pipeline under development by OBI Pharma Inc. TAIPEI, TAIWAN / — A team led by Dr. Chi-Huey Wong, Distinguished Research Fellow at Academia Sinica in …

OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference

SAN FRANCISCO, CA. January 8, 2019 /PRNewswire/ — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Amy Huang, General Manager, will present a company overview at the 37th …